Visceral Pain Treatment Market Size to Exceed USD 23.72 Bn by 2032

The Visceral Pain Treatment Market, estimated at USD 16.09 Bn in 2025, is expected to exhibit a CAGR of 5.7% and reach USD 23.72 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The strategies adopted by key market players like up-gradation of launched products is expected to drive the global visceral pain treatment Market growth over the forecast period. For instance, on May 25, 2025, Ironwood Pharmaceuticals, Inc., a healthcare company, presented new findings at the 2025 Digestive Disease Week (DDW) meeting that suggest colonic IW-3300 may help relieve gastrointestinal pain in patients with gastrointestinal disorders. An oral presentation entitled Colonic administration of the guanylate cyclase C agonist IW-3300 , Ironwood is currently developing IW-3300, a guanylate cyclase-c (GC-C) agonist, for the potential treatment of visceral pain conditions such as interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis which alleviates chronic pelvic pain and somatic pain in a rat model of early life stress-induced colonic hypersensitivity (presentation #240) showed that colorectal administration of IW-3300 prevents overlap chronic pelvic pain in a preclinical model of early-life stress-induced colonic hypersensitivity.

Global Visceral Pain Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems regarding the transportation of drugs from one place to another.

COVID-19 had a negative impact on the global visceral pain treatment market due to the increasing disruption of normal lives of people due to nationwide lockdowns and increasing COVID infection. For instance, according to an article published by Transform Manual Physical Therapy on September 7, 2025, Visceral Manipulation (VM) is a gentle manual therapy that works with organs and aids body’s ability to restore health. Optimum health requires a harmonious relationship of organ movement and fluid dynamics that can be impacted by viruses such as COVID-19 as well as other infections, trauma, surgery, pollution, and diet. When an organ is restricted or unhealthy it causes the body to compensate. This creates abnormal tension which can also lead to structural problems that do not necessarily correlate with an organ. Every breath requires movement but the scar alters the movement pattern. This could not only impact the ability to breathe fully, but contribute to neck, shoulder, or mid-back pain.

Global Visceral Pain Treatment Market: Key Developments

Increasing research to reduce pain is expected to drive the market growth

For instance, on September 2, 2025, Springer Nature, journal based in U.S. published an article explaining that the development of autonomic nerve blocks have been described in the treatment of pain. In particular, celiac ganglion blockade has been reported in the treatment of chronic pain due to malignancy in the foregut or pancreatitis. In these patients, neuraxial blocks have been shown to be a safe and effective treatment for chronic pain. However, Paragastric Autonomic Nerve Block (PG-ANB) has not been performed as part of perioperative multimodal pain management algorithms in gastrointestinal surgeries. The two main proposed mechanisms of action of this autonomic blockade are the reduction of gastric parasympathetic influence, which reverses its increased muscle tone and deactivates mechanoreceptors in the walls of the organ.

Browse 40 Market Data Tables and 45 Figures spread through 230 Pages and in-depth TOC on Global Visceral Pain Treatment Market, By Drug Type (Pain Modifiers (Tricyclic Anticonvulsant and Tricyclic Antidepressants), Analgesics (Narcotics and NSAID), and Others ) By Indications (Chronic Prostatitis, Interstitial Cystitis, Crohn’s Disease, and Irritable Bowel Syndrome) and By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, and Online Channels) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/visceral-pain-treatment-market-4095

Key Takeaways of the Global Visceral Pain Treatment Market:

• The global visceral pain treatment market is expected to exhibit a CAGR of 5.7% during the forecast period. For instance, Verywell Health, a U.S.-based healthcare publishing company, on April 7, 2025, published an article explaining that visceral pain can be an expected or relatively harmless condition. For example, patients will feel visceral pain while healing from surgery, and might have a pattern of recurrent visceral pain if patient have a "sensitive stomach." New and/or unexpected visceral pain could also be a sign of a medical problem. However, since there is a possibility of radiating pain and referred pain, the underlying cause can be hard to spot.
• Among drug type, analgesics is expected to be the dominant segment in the global visceral pain treatment market owing to the increasing treatments for visceral pain. For instance, Verywell Health, on April 7, 2025, published an article explaining medications such as some Over-the-counter (OTC) Non-steroidal Anti-inflammatories (NSAIDs) such as Aleve (naproxen) and aspirin (acetylsalicylic acid) can help with the pain. However, since some of these medications are blood thinners, they can also make some causes of visceral pain worse. Tylenol (acetaminophen) is generally safe for the treatment of visceral pain.
• Among region, North America is expected to be the dominant region in the global visceral pain treatment market, owing to the increasing treatments for visceral pain. On April 7, 2025, Verywell Health, explained about the pain medications as opioids, such as codeine and morphine, may be used to treat severe pain. Opioids can cause side effects such as constipation and drowsiness, and can also lead to tolerance and/or dependence. When used temporarily, these effective medications can help manage postoperative pain or relieve pain until the cause is identified and properly treated.
• The major players operating in the global visceral pain treatment market include Addex Therapeutics Ltd., AstraZeneca, Astellas Pharma Inc., Allergan, Chromocell Corporation, Takeda, GIcare Pharma Inc., Abbvie, Grunenthal GmbH, Johnson & Johnson, Neurim Pharmaceuticals Ltd, and Medestea Research & Production S.p.A.